
Novartis has settled patent litigation with Sun Pharmaceutical Industries in the US, paving the way for the Indian company’s subsidiary …

Novartis has been delivered a blow by the US Food and Drug Administration as the regulator says it needs further …

European Union regulators are considering whether they need to take any action over the recent allegations of anti-competitiveness involving Roche …

Bayer is in talks with Merck & Co to buy its consumer business and is willing to pay $14 billion …

GlaxoSmithKline has seen revenue and profit plummet in the first quarter of 2014. The UK-based company saw turnover fall 13% …

Novartis’ ‘breakthrough’ drug Zykadia has been approved by the FDA to treat lung cancer patients with a particular genetic mutation. …
Multiple sclerosis drug Gilenya and cancer treatment Afinitor were among the biggest sellers for Novartis, as the Swiss company’s net …

In the latest proposal in a flurry of merger and acquisition activity in the pharma sector, Valeant Pharmaceuticals International wants …
GlaxoSmithKline and Novartis are radically shaking up their businesses, starting up a joint venture while selling off major parts of …

Novartis has hired specialist consultancy firm PharmaVentures to help it decide how to re-use it former Horsham site. This comes …

French competition authorities are investigating Roche and Novartis in connection with their marketing of Lucentis for wet age-related macular degeneration …

PatientsLikeMe has set up a five-year agreement with Genentech, Roche’s biologics arm, to allow the firm access to patients’ real-world …

India’s status as a battleground for patent issues has been reinforced with the news that Novartis is suing Biocon over …

The prospects of Novartis’ latest heart drug being approved in the US anytime soon appear to have been scuppered by …